[go: up one dir, main page]

CN1429118A - 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 - Google Patents

芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 Download PDF

Info

Publication number
CN1429118A
CN1429118A CN01809581A CN01809581A CN1429118A CN 1429118 A CN1429118 A CN 1429118A CN 01809581 A CN01809581 A CN 01809581A CN 01809581 A CN01809581 A CN 01809581A CN 1429118 A CN1429118 A CN 1429118A
Authority
CN
China
Prior art keywords
her2
aromatase inhibitor
antibody
exemestane
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01809581A
Other languages
English (en)
Chinese (zh)
Inventor
G·马斯米尼
G·皮斯特里
D·普兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn SpA
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA, Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn SpA
Publication of CN1429118A publication Critical patent/CN1429118A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01809581A 2000-05-15 2001-04-19 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 Pending CN1429118A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
US09/571,355 2000-05-15

Publications (1)

Publication Number Publication Date
CN1429118A true CN1429118A (zh) 2003-07-09

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01809581A Pending CN1429118A (zh) 2000-05-15 2001-04-19 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂

Country Status (20)

Country Link
EP (1) EP1282440A1 (es)
JP (1) JP2003533490A (es)
KR (1) KR20030014223A (es)
CN (1) CN1429118A (es)
AU (1) AU784617B2 (es)
BR (1) BR0110732A (es)
CA (1) CA2409652A1 (es)
CZ (1) CZ20023748A3 (es)
EA (1) EA005931B1 (es)
EE (1) EE200200622A (es)
HK (1) HK1054200A1 (es)
HU (1) HUP0301877A2 (es)
IL (1) IL152389A0 (es)
MX (1) MXPA02011194A (es)
NO (1) NO20025302L (es)
NZ (1) NZ523004A (es)
PL (1) PL360153A1 (es)
SK (1) SK16022002A3 (es)
WO (1) WO2001087334A1 (es)
ZA (1) ZA200209815B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
CN102068429A (zh) * 2010-12-28 2011-05-25 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
EP1551452A4 (en) * 2002-07-01 2006-08-30 Savient Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CN113633644A (zh) 2014-10-22 2021-11-12 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
CN102068429A (zh) * 2010-12-28 2011-05-25 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法

Also Published As

Publication number Publication date
EE200200622A (et) 2004-06-15
EP1282440A1 (en) 2003-02-12
HK1054200A1 (zh) 2003-11-21
PL360153A1 (en) 2004-09-06
NO20025302D0 (no) 2002-11-05
ZA200209815B (en) 2003-12-03
IL152389A0 (en) 2003-05-29
AU5630901A (en) 2001-11-26
SK16022002A3 (sk) 2003-04-01
JP2003533490A (ja) 2003-11-11
NO20025302L (no) 2002-11-05
AU784617B2 (en) 2006-05-18
BR0110732A (pt) 2003-02-04
EA200201213A1 (ru) 2003-04-24
EA005931B1 (ru) 2005-08-25
KR20030014223A (ko) 2003-02-15
WO2001087334A1 (en) 2001-11-22
NZ523004A (en) 2004-09-24
HUP0301877A2 (hu) 2003-09-29
CA2409652A1 (en) 2001-11-22
CZ20023748A3 (cs) 2003-04-16
MXPA02011194A (es) 2003-03-10

Similar Documents

Publication Publication Date Title
CN1429118A (zh) 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂
AU2001239913B2 (en) Method of treating cancer with anti-neurotrophin agents
US20050032759A1 (en) Antitumor combined therapy
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
IL295098B1 (en) Combinations of trastuzumab-mcc-dm1 and 5-fu for use in treatment of a cancer expressing erbb2
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2023085422A (ja) 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
EP4653019A1 (en) Anti-her2 antibody-drug conjugate for treating breast cancer
EP3449939B1 (en) Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
JPWO2022033978A5 (es)
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054200

Country of ref document: HK